MedTrace Logo

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

NCT06134232 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-08-27

No results posted yet for this study

Summary

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Conditions

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

Sipuleucel-T Injection

Single Infusion

Sponsors & Collaborators

  • WCG IRB

    collaborator UNKNOWN

  • Talosix

    collaborator UNKNOWN

  • Dendreon

    lead INDUSTRY

Principal Investigators

  • Nadeem Sheikh, PhD · Dendreon Pharmaceuticals, LLC

  • Benjamin Lowentritt, MD · Chesapeake Urology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2031-12-31
Completion
2032-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06134232 on ClinicalTrials.gov